San Diego, Calif. – February 26, 2014 – Cooley LLP announced today that it advised Flexion Therapeutics on its $74.8 million IPO. Flexion is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel pain therapies. The company now trades on the NASDAQ Global Market under the symbol "FLXN."
The Cooley corporate and securities team that advised Flexion included partners Tom Coll, Marc Recht and Sean Clayton, as well as associates Rob Hadfield, Jon Russo, Scott Tanner, Terren O'Connor, Anna Jarosinski, Dani Nazemian and Jessica Wade. Critical Support for the offering was provided by partner Natasha Leskovsek (regulatory); associate Megan Arthur (compensation & benefits); and partner Erich Veitenheimer and associates Angela Purcell and Sandhya Deo (intellectual property).
In 2013, Cooley's capital markets practice had a record year, advising on 60 public offerings, including 23 IPOs that raised more than $8.4 billion. Year-to-date in 2014, Cooley has advised on 24 completed public offerings, including 13 completed IPOs. Last year, Cooley attorneys also handled more than 120 M&A transactions, with an aggregate deal value of more than $12.4 billion.
About Cooley LLP
Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.
Cooley has more than 750 lawyers across 11 offices in the United States and China.